Multimodal Computational Framework Can Predict Prognosis of Myelodysplastic Syndromes
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 26, 2025 -- A multimodal computational framework for patient stratification and prognosis prediction enables automatic identification of patient clusters, outperforming classical approaches for patients with myelodysplastic syndromes (MDS), according to a study published online in the April issue of Computer Methods and Programs in Biomedicine.
Cesare Rollo, from the University of Torino in Italy, and colleagues introduced a multimodal computational framework for patients' stratification and prognosis prediction (VAE-Surv). VAE-Surv integrates a variational autoencoder (VAE), which reduces the high-dimensional space that characterizes molecular data, with a deep survival model, combining embedded information with clinical features. The clinical robustness of the algorithm was tested by applying VAE-Surv to the Genomed4All cohort of MDS.
The researchers found that VAE-Surv achieved a median C-index of 0.78 when tested on 2,043 patients in the GenomMed4All cohort, outperforming classical approaches. Compared with a traditional approach that applies the clustering directly to the input data, the latent space enhanced the clustering performance. The analysis of the identified clusters showed that the proposed framework can capture existing clinical categorizations compared with the World Health Organization 2016 MDS subtypes while also suggesting novel, data-driven patient groups. VAE-Surv achieved a good prediction performance when tested in an external MDS cohort of 2,384 patients (median C-index, 0.74), preserving the interpretability of the main clinical and genetic features.
"VAE-Surv framework demonstrates the power of deep learning in handling the intricate genetic landscape of MDS, offering a novel, robust methodology for patient stratification and survival prediction," the authors write. "It stands to contribute significantly to personalized medicine in the context of hematologic disorders."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Few With Myelodysplastic Syndromes Receive Hypomethylating Agents
MONDAY, Aug. 11, 2025 -- Few patients with myelodysplastic syndromes (MDS) receive treatment with hypomethylating agents (HMAs), with evidence of age-, sex-, and race-related...
Inflammation and Nutrition-Based Scores Tied to Prognosis of Low-Risk Myelodysplastic Syndrome
THURSDAY, July 24, 2025 -- The Prognostic Nutritional Index (PNI) and systemic oxidative stress (SOS) score are independently associated with poorer prognosis of low-risk...
Allogeneic HCT Feasible in Older Patients With Myelodysplastic Syndrome
WEDNESDAY, July 23, 2025 -- Allogeneic hematopoietic cell transplantation (allo-HCT) is feasible in older patients with myelodysplastic syndrome (MDS), according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.